# Selective mTOR inhibition via FLCN drives TFE3-dependent VLDL-TG secretion and protects from MAFLD/MASH

Source: [nature.com](https://www.nature.com/articles/s41467-026-79397-6) · 2026-11-18 · Life
Page: https://themorning.science/story/selective-mtor-inhibition-via-flcn-drives-tfe3-dependent-vldl-tg-secretion-and-p-63f443de3d265475
Kind: research · Impact: medium

## In brief

- A Nature Communications study reports a pathway in which selective, non-canonical mTOR signaling via FLCN regulates VLDL assembly and secretion.
- The pathway involves TFE3-dependent VLDL-triglyceride secretion from the liver.
- The authors report that targeting this pathway efficiently suppresses liver steatosis (fatty liver) and protects against MAFLD/MASH.

## Why it matters

It identifies a mechanism linking mTOR signaling to hepatic lipid export, a potential target for fatty liver disease (MAFLD) and its progression to MASH.

## Timeline

- 2026-11-18: Study published online in Nature Communications (doi:10.1038/s41467-026-79397-6)

## Coverage

- [Selective mTOR inhibition via FLCN drives TFE3-dependent VLDL-TG secretion and protects from MAFLD/MASH](https://www.nature.com/articles/s41467-026-79397-6) — nature.com, 2026-11-18

Tags: mtor, vldl, fatty liver, mash, metabolism, flcn

---

Brief generated by AI (claude-haiku-5-5) from the reporting listed under Coverage. Headlines belong to their publishers. The Morning Science – https://themorning.science
